Glucose lowering to control macrovascular disease in type 2 diabetes: treating the wrong surrogate end point?

JAMA. 2008 Nov 5;300(17):2051-3. doi: 10.1001/jama.2008.510.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / therapy*
  • Diabetic Angiopathies / etiology
  • Diabetic Angiopathies / prevention & control*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin Resistance*

Substances

  • Hypoglycemic Agents